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Numerous well-characterized growth factors play an important
role in regulating the growth and development of the mammalian
mammary gland. The expression and secretion of some of these
growth factors are under the control of ovarian hormones and
probably act as important autocrine and paracrine modulators that
can regulate end bud, ductal and alveolar growth and develop-
ment. Likewise, a number of growth factors and growth inhibitors,
including EGF, TGFa TGFb, amphiregulin, Cripto-1, heregulin,
heparin binding-EGF and plateled-derived growth factor are
synthesized by malignant mammary epithelial cells (Ciardiello
et al, 1989; Normanno et al, 1994a, b; Qi et al, 1994). Most of
them have been demonstrated to function as either positive or
negative autocrine growth regulators in vitro in a variety of human
breast cancer cell lines (Kenney et al, 1993; Souttou et al, 1994). 
A number of growth factors are also described to participate in
the regulation of the plasminogen activator (PA)/plasmin system
(Rosenthal et al, 1998). PA are serine proteases, catalysing the
conversion of plasminogen to plasmin. Plasmin exhibits a wide array
of physiological and pathological processes, such as tissue growth
and remodelling, tumour invasion and metastasis (Andreasen et al,
1997). Two classes of proteases, serine proteinases and the metallo-
proteinases, and their inhibitors, have been studied extensively in
breast and other cancers. Many studies have focused on the role of
urokinase-type plasminogen activator (uPA) and have described a
correlation between uPA expression and cell invasion and metastasis
(Foeckens et al, 1992). Type-1 plasminogen activator inhibitor (PAi-
1) may also be directly involved in cancer progression, and an
increasing number of clinical studies have demonstrated that high
PAi-1 levels indicate a poor prognosis for the survival of patients
suffering from a variety of cancers (Bouchet et al, 1994). 
Among EGF-related growth factors, amphiregulin (AR) seems
to play special physio-pathological role in the human mammary
gland. Amphiregulin is a heparin-binding growth factor initially
purified from conditioned medium of breast cancer epithelial
MCF-7 cells treated with phorbol 12-myristate 13-acetate (Shoyab
et al, 1988). Whereas AR binds and activates EGF-receptor (c-erb
B1), direct interaction of AR with other members of the c-erb B
family has not been reported (Johnson et al, 1993a). AR is
expressed in several tissues, such as human ovary, placenta, lung,
kidney, stomach, colon and breast (Johnson et al, 1992; Lejeune
et al, 1993). Increased evidences strongly suggest that AR may
function as a potential autocrine growth factor in tumoral as well
as in their counterpart normal cells, such as prostatic (Sehgal et al,
1994), colonic (Johnson et al, 1992; Normanno et al, 1995), and
mammary epithelial cells (Li et al, 1992; Normanno et al, 1994a,
b). Moreover, overexpression of AR has been detected in several
oestrogen-responsive and -unresponsive breast cancer cell lines as
well as in approximately 80% of human primary breast carcinoma
(Martinez-Lacaci et al, 1995; Visscher et al, 1997). More import-
ant, overexpression of AR, but not that of TGFa or Cripto, appears
as an independent prognostic indicator correlated with a diminu-
tion of survival for patients with non-small-cell lung cancer
(Fontanini et al, 1998). 
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Summary Amphiregulin (AR) is a heparin-binding epidermal growth factor (EGF)-related peptide that seems to play an important role in
mammary epithelial cell growth regulation. We have investigated the regulation of AR-gene expression and -protein secretion by EGF in
normal breast epithelial cells (HMECs), as well as in the tumoral breast epithelial cell lines MCF-7 and MDA-MB231. EGF induced a dose-
dependent increase of AR mRNA level in both normal and tumoral cells. Thus, 1028 M EGF stimulated AR expression in HMECs to
140–300% of control. A similar EGF concentration increased AR mRNA level to 550% and 980% of control in MCF-7 and MDA-MB231 cells,
respectively. This was accompanied by an accumulation of AR into conditioned culture media. However, HMECs secreted in response to
EGF, 5–10 fold more AR than tumour cells. Furthermore, the potential participation of AR in the regulation of the plasminogen activator
(PA)/plasmin system was investigated. Whereas HMEC-proliferation was stimulated by AR, the levels of secreted urokinase-type
plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAi-1) remained unaffected. Conversely, AR failed to regulate the
proliferation of tumoral cell lines but induced an accumulation of uPA and PAi-1 into culture media. This was accompanied by an increase
of the number of tumoral cells that invaded matrigel in vitro. Moreover, the presence of a neutralizing anti-uPA receptor antibody reversed the
increased invasiveness of MDA-MB231 cells induced by AR. These data reveal differential behaviour of normal versus tumoral breast
epithelial cells in regard to the action of AR and demonstrate that, in a number of cases, AR might play a significant role in tumour progression
through the regulation of the PA/plasmin system. © 2001 Cancer Research Campaign http://www.bjcancer.com
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Whereas the expression of AR in a variety of both non-
transformed and tumoral cells appears to be stimulated in the pres-
ence of EGF (Normanno et al, 1994b; Sehgal et al, 1994), the
potential regulation of AR by growth factors in normal breast
epithelial cells has never been examined. Because previous studies
suggest that dysregulated expression of AR may be a component
of mammary tumorigenesis we proposed to analyse and to
compare the regulation of amphiregulin gene expression and
protein secretion by EGF in normal and tumoral breast epithelial
cells. Moreover, our aim was to examine potential role of AR in
the regulation of uPA and PAi-1 protein secretion that could
account for breast cancer progression. 
MATERIAL AND METHODS 
Materials 
Anti-smooth muscle a-actin, -actin, -vimentin and -cytokeratin 14,
18 and 19 antibodies were provided by Sigma (St Quentin
Fallavier, France); Anti-vimentin antibody was from DAKO
(Denmark). The AR cDNA probe was obtained from Dr. Plowman
(Bristol-Myers Squibb, Seattle, WA). Matrigel was provided by
Becton-Dickinson (France). Anti-uPA receptor neutralizing anti-
body, recombinant human AR and AR enzyme-immunoassay kit
were from R & D Systems (Abingdon, UK). Antibodies used in
ELISA determination of AR recognize various forms of promature
and mature human AR of 12–46 kDa. They show no cross-
reactivity with other members of the EGF-related growth factors,
as well as with a large variety of other cytokines. PAi-1 and uPA
ELISA kits were from American Diagnostic Inc (Greenwich, CT).
PAi-1 ELISA detects latent and active forms of human PAi-1 and
PAi-1 complexes. The assay is insensitive to PAi-2. Inactive and
active forms of uPA are all recognized by the uPA ELISA kit, as is
receptor-bound uPA and uPA complexed with PAi-1 and PAi-2. 
Culture of breast cancer epithelial cell lines 
The MCF-7 cell line, derived from human breast adenocarcinoma
was obtained from Dr M Lippman (NIH, Bethesda). Cells were
maintained in 50% (vol/vol) Dulbecco’s modified Eagles medium
(DMEM) and 50% (vol/vol) Ham’s F12 medium (F12), supple-
mented with 10% heat-inactivated fetal calf serum (FCS), 2 mM
L-glutamine and 6 ng ml21 human insulin. The MDA-MB231
cells obtained from Mason Research Institute were cultured in
Leibovitz L15 medium containing 10% FCS, 2 mM L-glutamine,
10 mM Hepes, 0.01% non essential amino acids (Gibco BRL) and
3.6 mg ml21 insulin. MCF-7 cells were maintained at 37˚C in
a humid atmosphere of 5% CO2 in air, and MDA-MB231 cells in a
humid atmosphere of air. Before experimentation, cells were
grown for one week in medium containing steroid-depleted serum. 
Primary culture of normal breast epithelial cells 
Epithelial cell cultures were grown from tissue specimens
obtained after their informed consent from 5 women between 16
and 44 years of age who underwent reduction mammoplasty for
cosmetic reasons. The time of the menstrual cycle was noted for
every patient. These patients had no history of breast disease and
normal state of breast samples was verified by histo-pathological
examination. Tissues were mechanically dissociated with scis-
sors then incubated at 37˚C with constant shaking in medium
containing 150 U ml21 hyaluronidase (Sigma) and 250–500 U
ml21 collagenase (Sigma). Digestion was monitored under an
inverted microscope. Released organoids were then separated by
density gradient centrifugation using 1.077 g ml21 lymphocyte
separation medium. Organoids were then plated in DMEM/F12
(1/1, vol/vol) containing 10 mM Hepes, 2 mM glutamine, 10 mg
ml21 insulin, 5 ´ 1026 M cortisol, 50 U ml21 penicillin, 50 mg ml21
streptomycin, 100 ng ml21 cholera toxin, 2 ng ml21 EGF and 5%
FCS (B1 medium). Cells were cultured at 37˚C in a 5% CO2–95%
air atmosphere. One week following the plating, medium was
replaced by the same medium containing 60 mM CaCl2 instead of
1.05 mM (B2 medium). Cells were sub-cultured by the transfer of
floating cells. Before experimentation, cells were grown for one
week in steroid-depleted B1 medium deprived of EGF and cholera
toxin. The epithelial phenotype of cultured cells was verified by
immuno-cytochemistry, using monoclonal antibodies specific for
the following proteins: cytokeratins 14, 18 and 19, smooth muscle
a-actin, actin and vimentin. 
Cell proliferation assay 
Cell growth determination was performed in 6 well-culture plates.
Cells were seeded in culture medium containing 1% steroid-
depleted serum. They were allowed to grow for 3 days then treated
with different concentrations of EGF or AR (10212 M–1028 M).
Treatments were performed for 5 days and renewed every 2 days.
At the end of the treatment, cells were harvested and cell number
was determined using a cell counter. 
Preparation of conditioned medium, and amphiregulin
and protease measurements 
Cells were seeded in 6 well-culture plates, in culture medium
supplemented with 1% steroid-depleted FCS. 3 days later, cells
received different concentrations of EGF or AR (10210 M–1028
M). Cells were treated for 2 days, then treatments were continued
in serum-free culture medium for 24 h. Conditioned media were
collected and particulates were removed by centrifugation.
Quantitative determination of human amphiregulin, PAi-1 and uPA
concentrations was performed using enzyme-immunoassay kits,
according to the instructions of the manufacturers. 
Invasion assay 
Invasion assays were carried out in Transwell culture system
(Costar Corporation, France). Briefly, 6.4 mm-diameter filters (8
mm pores) of cell culture inserts were coated with 12 mg filter–1 of
reconstituted basement membrane Matrigel diluted with ice-cold
distilled water. Matrigel was allowed to dry overnight then recon-
stituted with DMEM/F12 medium for 90 min at room temperature.
Uniformity of the coating was verified by coomassie blue staining
and microscopic observation. Exponentially growing cells were
plated in the inserts (15 000 cells insert21). MCF-7 and MDA-
MB231 cells were grown in their respective culture medium
containing 1% steroid-depleted FBS. NBECs were cultured in
EGF- and cholera toxin-free B1 medium supplemented with 1%
steroid-depleted FBS. The inserts were then placed into the wells
of 24 well-culture plates. Amphiregulin at 1028 M was added
in the upper compartment, whereas fibronectin (15 mg ml21)
was placed in the lower compartment as a chemoattractant.
Culture medium and treatments were renewed every 2 days. Afterincubation at 37˚C for 5 days, the cells on the upper surface of the
filter were removed with a cotton swab. The cells that had
traversed the matrigel and attached to the lower part of the filter
were fixed, stained with Harris haematoxylin and counted in 15
randomly selected microscopic fields. 
Isolation of cellular RNA 
Cells were plated into 150 cm2 T-flasks in medium containing
1% steroid-depleted serum. 3 days later cells were treated in the
absence or in the presence of various concentrations of EGF
(10–10 M–1028 M). Treatments were performed for 2 days, then
RNA extraction was carried out using RNazol (Cinna-Biotex,
Friendswood, Texas, USA). After addition of equal volumes
of chloroform, extracted RNA was precipitated with one volume
of isopropanol. After washing, pellet was resuspended in 20–40 ml
DEPC-water. 
Reverse transcription 
First strand cDNA was synthesized by using Moloney mouse
leukaemia virus (MMLV) reverse transcriptase. 5 mg of total RNA
extracted as previously described was incubated with oligo(dT)
(1 mg per reaction) and DEPC-water (qsp 6 ml) for 10 min at 65˚C,
then for 5 min at 0˚C. Reverse transcription was then initiated in
the presence of 2 ml of MMLV (400 U), 5 ml of 5-fold concen-
trated reaction buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15
mM MgCl2), 1 ml of 10 mM dNTP, 2 ml of 100 mM dithiothreitol
and 0.5 ml RNase inhibitor (40 U ml21). Reaction was performed
for 1 h at 37˚C then for 30 min at 52˚C. 
Polymerase chain reaction and Southern blot analysis 
Co-amplifications of the AR and b2-microglobulin cDNAs, and
Southern blot analysis of the PCR products were performed as
reported previously (Silvy et al, 1998). Briefly, 30 ml of the PCR
products were separated by electrophoresis in 3% agarose gel. The
gel was stained with ethidium bromide to allow the visualization
of DNA that was then denatured and transferred to a Hybond N
membrane (Amersham). The amphiregulin-cDNA probe was
labelled with [a-32P]dCTP using the random priming method
(Feinberg and Vogelstein, 1983). The b2-microglobulin probe was
labelled with [g-32P]dCTP using the T4 kinase enzyme. 
Image acquisition and analysis 
The autoradiographies were scanned with the AGFA ARCUS TM
scanner (Agfa-Geavaert AG) in the transparency mode. The
resolution of the scanner is adjustable from 1 to 1200 pixel per
inch (ppi). The software used in the analysis was the Macintosh-
based public domain program Image, written by Rasband at the
National Institute of Health (NIH). The program contains a built-in
macro language permitting complicated repetitive procedures to
be converted to single commands as we use here. The Integrated
Optical Density (IOD) of each band was measured with a
background subtraction. 
Statistical analysis 
All values were expressed as mean ± SE. Student’s t-test was used
for comparisons between experimental data. A value of P < 0.05
was considered to be statistically slightly significant (*); a value of
P < 0.01, statistically significant (**); and a value of P < 0.001,
highly significant (***). 
RESULTS 
Immunophenotyping of normal human mammary
epithelial cells 
The epithelial phenotype of normal human mammary epithelial
cells (HMECs) was verified by immuno-cytochemical assay
(Table 1). The positive immuno-staining for cytokeratins 18 and
19 in the majority of the cells confirmed the epithelial nature of the
primary cultures. In some primary cultures, very weak vimentin-
and cytokeratin 14-stainings were observed in less than 20% of
cells and the large majority of cells appeared negative for actin,
suggesting the almost total absence of myoepithelial cells. More-
over, smooth muscle a-actin appeared to be undetectable in all the
samples analysed. 
Effect of EGF on AR expression and secretion in
normal and tumoral breast epithelial cells 
The effect of EGF on AR expression was examined in the breast
cancer cell lines MCF-7 and MDA-MB231 as well as in a panel of
normal breast epithelial cells in primary culture. The variations
938 M Silvy et al
British Journal of Cancer (2001) 84(7), 936–945 © 2001 Cancer Research Campaign
Table 1 Immunophenotyping of normal breast epithelial cells in primary culture 
Sample no. Age CK14 CK18 CK19 a-Actin Actin Vimentin 
SN52 16 + (<20) ++ (>90) + (>80) – – + (<20) 
SN53 26 + (<20) ++ (>90) + (>90) – – + (<20) 
SN48 28 – ++ (>90) ++ (>90) – – – 
SN47 44 – ++ (>90) + (>80) – – + (<20) 
SN50 ND – ++ (>90) ++ (>90) – – – 
The epithelial phenotype was verified by immunocytochemical assay as described in ‘Materials and
methods’. –, no staining; +, low staining; ++, strong staining. Numbers in parenthesis indicate the
percentage of positive cells. ND, not determined. of AR mRNA level induced by various concentrations of EGF
were evaluated by RT-PCR. In both tumoral cell lines, EGF was
demonstrated to induce an important stimulation of AR expression
(Figure 1). However, the augmentation of AR mRNA level induced
by EGF was more elevated in MDA-MB231 than in MCF-7 cells.
Thus, cell treatment with 1028 M EGF increased AR mRNA level
to 550% and 980% of control in MCF-7 and MDA-MB231 cells,
respectively. A dose-dependent accumulation of the secreted
protein in the culture medium of both cell lines was also observed
in response to EGF. However, the amplitude of this accumulation
was moderate (Table 2). Thus, in the presence of 1028 M EGF, the
level of AR secreted by MCF-7 cells attained 270% of control. In
the MDA-MB231 cell line, a similar EGF concentration induced
a slight but significant augmentation of secreted AR (180% of
control). Decreased doses of EGF were unable to affect the accu-
mulation of AR in culture medium of these cells. Moreover, the
level of cell-associated AR appeared little affected by EGF since
AR level measured in cell homogenate attained 130% and 150% of
control in MDA-MB231 and MCF-7 cells, respectively (Table 2). 
EGF was also able to increase AR expression in normal breast
epithelial cells in primary culture. The EGF-induced AR mRNA
stimulation was dose-dependent and varied from 140% to 350% of
Growth factors and protease in breast epithelial cells 939
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Figure 1 Effect of EGF on AR mRNA level in MDA-MB231 and MCF-7 cells. Studies were performed on cells treated for 48 h with EGF at the indicated
concentrations. AR and b2-microglobulin mRNA levels were assayed by RT-PCR. The 165 pb b2-microglobulin and 136 bp AR amplified fragments were probed
as described in Material and Methods with [a-32P]dCTP-labelled probes. After autoradiography, the integrated optical density of each band was measured with a
background subtraction as indicated in Material and Methods. Values obtained for each sample were corrected for the corresponding b2-microglobulin mRNA
level. Data are the mean ± SD of values obtained from 3 separate experiments and are expressed as percentage of control. ***, significantly different from the
control by Student’s test with P < 0.001 
Table 2 Effect of EGF on the level of AR protein in tumoral breast epithelial cells 
AR, pg per 106 cells 
Conditioned medium Cell homogenate 
MCF-7 MDA-MB231 MCF-7 MDA-MB231 
Control 75 ± 8 (100) 53 ± 11 (100) 56 ± 12 (100) 36 ± 10 (100) 
EGF 10–10 M 60 ± 7 (80) 52 ± 9 (98) 51 ± 5 (91) 42 ± 4 (116) 
EGF 10–9 M 155 ± 21 (206) 50 ± 4 (94) 63 ± 13 (112) 40 ± 10 (111) 
EGF 10–8 M 203 ± 19 (270) 97 ± 11 (180) 86 ± 12 (153) 48 ± 11 (130) 
Cell homogenates and conditioned medium produced by untreated and EGF-treated cells was prepared as
described in ‘Material and Methods’ and the level of AR was determined by enzyme-immunoassay. The data are
the mean +/– SD of two separate experiments. Values in parenthesis are expressed as percentage of control. 940 M Silvy et al
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control, depending upon the samples analysed (Figure 2). This was
accompanied by an important augmentation of the level of
secreted protein. Thus, in the presence of 1028 M EGF, the accu-
mulation of AR in conditioned medium produced by the normal
epithelial cells SN52 and SN47 attained 550% and 680% of
control, respectively (Table 3). Similar high level of protein accu-
mulation was observed for SN53, SN48 and SN50 cells when
treated with EGF (not shown). By contrast, moderate increase
(150–200%) of cell-associated AR could be detected in HMEC
homogenates in response to EGF (Table 3). 
Effect of AR and EGF on cell proliferation and protease
secretion in normal and tumoral breast epithelial cells 
The ability of AR to regulate cell proliferation, PAi-1 and uPA
secretion was evaluated in normal and tumoral breast epithelial
cells. As illustrated in Figure 3, AR added in cell culture medium
was unable to affect the proliferation of the breast cancer epithelial
cell lines MCF-7 and MDA-MB231. On the contrary, AR induced
a stimulation of PAi-1 and uPA secretion by MDA-MB231 cells,
in a dose-dependent manner. Thus, treatment of these cells with
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Figure 2 Effect of EGF on AR mRNA level in normal mammary epithelial cells in primary culture. Studies were performed on 5 different samples, treated for
48 h with EGF at the indicated concentrations. AR and b2-microglobulin mRNA expression levels were assayed by RT-PCR and Southern blot analysis as
described in Materials and Methods. Values obtained for each sample were corrected for the corresponding b2-microglobulin mRNA level. Data are the mean ±SD
of values obtained from 3 separate experiments and are expressed as percentage of control. *, **, and ***, significantly different from the control by Student’s
test with P < 0.05, P < 0.01 and P < 0.001, respectively
Table 3 Effect of EGF on the level of AR protein in normal breast epithelial cells 
AR, pg per 106 cells 
Conditioned medium Cell homogenate 
SN52 SN47 SN52 SN47 
Control 204 ± 22 (100) 413 ± 51 (100) 180 ± 19 (100) 216 ± 31 (100) 
EGF 10–10 M 462 ± 28 (226) 500 ± 35 (120) 172 ± 23 (95) 241 ± 17 (111) 
EGF 10–9 M 626 ± 71 (306) 1166 ± 53 (280) 256 ± 21 (140) 392 ± 32 (181) 
EGF 10–8 M 1125 ± 83 (551) 2833 ± 112 (681) 281 ± 29 (156) 436 ± 26 (202) 
Cell homogenates and conditioned medium produced by untreated and EGF-treated cells was prepared as
described in ‘Material and Methods’ and the level of AR was determined by enzyme-immunoassay. The data are
the mean ± SD of two separate experiments. Values in parenthesis are expressed as percentage of control. 
Similar results were obtained for SN53, SN48 and SN50 normal breast epithelial cells. Growth factors and protease in breast epithelial cells 941
British Journal of Cancer (2001) 84(7), 936–945 © 2001 Cancer Research Campaign
1028 M AR increased both PAi-1 and uPA accumulation in condi-
tioned medium to 160% and 220% of control, respectively.
Similarly, in the presence of 1028 M AR, the levels of PAi-1 and
uPA secreted by MCF-7 cells were augmented to 200% of control.
In both tumoral cell lines, a slight augmentation (120–150% of
control) of cell-associated uPA and PAi-1 levels was detected in
response to 1028 M AR (not shown). In parallel, the effect of EGF
on cell proliferation and protease secretion was also examined. A
moderate stimulation (160% of control) of MDA-MB231 cell
proliferation was induced by 10210 M EGF. A dose-dependent
growth stimulation of MCF-7 cell line that attained 150% of
control in the presence of 1028 M EGF was observed. EGF was
also able to induce an accumulation of uPA and PAi-1 into condi-
tioned medium of both tumour cell lines. However, it appeared
less efficient than AR in stimulating protease production. 
In order to compare the biological activity of AR in normal
versus tumoral mammary tissue, a similar study was carried out on
a panel of normal mammary breast epithelial cells (HMECs) in
primary culture. Data reported in Figure 4 indicate that AR was
able to induce a dramatic dose-dependent stimulation of normal
epithelial cell proliferation. Thus, a growth-stimulatory effect was
observable by 10210 M AR. In the presence of 1028 M AR, HMEC
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Figure 3 Effect of EGF and AR on the proliferation, PAi-1 and uPA production by MDA-MB231 and MCF-7 cells. Cells were seeded in culture medium
containing 1% steroid-depleted serum and treated for 2 days with various concentrations of AR or EGF. Cells were then placed and treated in serum-free culture
medium for 24 h. Conditioned medium was collected and uPA and PAi-1 levels were determined by enzyme-immunoassay as described in Materials and
Methods. Basal levels of PAi-1 and uPA for MDA-MB231 cells were 85.3 ± 3.4 ng mg21 protein and 23.3 ± 2.30 ng mg21 protein, respectively. For MCF-7 cells,
PAI-1 and uPA basal levels were 356.2 ± 17.8 ng mg21 protein and 1.51 ± 0.06 ng mg-1 protein, respectively. In parallel, the effect of EGF and AR on cell
proliferation was assayed by the determination of cell number. All data are expressed as percentage of control and are the mean ± SD of values obtained from 3
separate experiments. *, **, and ***, significantly different from the control by Student’s test with P < 0.05, P < 0.01 and P < 0.001, respectively 942 M Silvy et al
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proliferation was stimulated to 400–500% of control, depending
on the samples examined. On the contrary, the accumulation of
both uPA and PAi-1 in conditioned medium of HMECs was not
affected by AR. In parallel, it was verified that the levels of cell-
associated uPA and PAi-1 were not modified in the presence of AR
(not shown). Similar results, regarding cell proliferation and
protease secretion, were obtained with EGF. 
Effect of AR on the invasive properties of MCF-7 and
MDA-MB231 cells 
The addition of 10210 M–1028 M AR in the upper compartment of
the invasion chamber allowed to a significant dose-dependent
increase of the number of tumoral cells that invaded the Matrigel
membrane (Table 4). Time course analysis indicated that the
number of invasive cells was maximal after 4–5 days of culture (not
shown). However, MDA-MB231 cells appeared more responsive
than MCF-7 cells to the invasive effect of AR. Thus, the presence
of 1028 M AR augmented the number of MCF-7 and MDA-
MB231 cells that had traversed the basement membrane to 160%
and 220% of control, respectively. Moreover, whereas 1029 M AR
was required to observe a significant increase of the number of
invasive MCF-7 cells (143% of control), a concentration of 10210
M AR appeared sufficient to significantly stimulate the invasive
properties of MDA-MB231 cells. Conversely, untreated HMECs
appeared unable to traverse matrigel, suggesting that, under our
experimental conditions, uPA may be produced as latent (inactive)
forms. Furthermore, the presence of AR (10210 M–1028 M) could
not induce significant migration of HMECs, even after 5 days of
culture (not shown). 
In order to further examine the potential role of uPA in the
increased invasiveness of tumoral cells treated with AR, a neutral-
izing anti-uPA receptor antibody was added into culture medium,
in the absence or in the presence of 1028 M AR. Results reported in
Table 3 indicate that the presence of the antibody was unable to
affect the invasive properties of both AR-treated and -untreated
MCF-7 cells. On the contrary, a moderate reduction of the number
of MDA-MB231 cells able to invade matrigel was observed when
cells were treated with the antibody alone. Furthermore, the anti-
body totally reversed the stimulatory effect of 1028 M AR on the
invasive activity of these cells, demonstrating that the increased
Table 4 Effect of AR and anti-uPA-R antibody on the invasiveness of MCF-
7 and MDA-MB231 cells 
Number of invasive cells (% of control) 
Treatments MDA-MB231 MCF-7 
Control 100 ± 6.2 100 ± 5.4 
AR 10210 M 140 ± 6.0a 107 ± 8.3 
AR 1029 M 197 ± 3.3b 143 ± 5.7a
AR 1028 M 220 ± 8.3b 162 ± 2.9b
a uPA2R 64 ± 2.4 97 ± 6.6 
AR 1028 M 112 ± 5.6c 166 ± 3.9 
+auPA-R 
Exponentially growing cells were harvested and added to invasion chambers
in the absence or in the presence of different concentrations of AR. The
involvement of uPA in cell invasiveness was evaluated by adding 10 mg ml21
anti-uPA-R antibody (a uPA-R), in the absence or in the presence of 1028 M
AR. Data are the mean ± SD of 3 independent experiments and are
expressed as the percentage of control (untreated cells). a, P < 0.01 versus
control; b, P < 0.001 versus control; c, P < 0.001 versus 1028 M AR. 
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Figure 4 Effect of EGF and AR on the proliferation, PAi-1 and uPA
production by normal mammary epithelial cells in primary culture (HMEC).
Experiments were performed as described in Figure 3. The results
presented have been obtained with HMECs SN48. Basal levels of PAi-1 and
uPA measured into conditioned culture medium were 318.7 ± 29.6 ng mg21
protein and 8.63 ± 0.95 ng mg21 protein, respectively. The samples SN47
and SN50 were also examined and allowed to similar results. Data are the
mean ± SD of triplicate determinations and are representative of 3 separate
experiments. All data are expressed as percentage of control. **, and ***,
significantly different from the control by Student’s test with P < 0.01 and
P < 0.001, respectivelyGrowth factors and protease in breast epithelial cells 943
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invasiveness of MDA-MB231 cells induced by AR was mediated
in large part by uPA. 
DISCUSSION 
AR, which has been described as a potent stimulator of prolifera-
tion in a variety of cell types, is expressed by epithelial cells in a
number of normal human tissues including the mammary gland
(Li et al, 1992; Panico et al, 1996). Moreover, AR has been shown
to act as an autocrine growth factor for normal human mammary
epithelial cells in vitro (Li et al, 1992; Kenney et al, 1993;
Normanno et al, 1994a, b) and its overexpression observed in
human malignancies such as breast cancers has been suggested to
be involved in tumoral cell growth disregulation (Normanno et al,
1994a, b; Visscher et al, 1997). In order to determine whether AR
can act as a mediator of the action of growth factors, we have
examined the regulation by EGF of AR-gene expression and 
-protein secretion, in normal and tumoral breast epithelial cells.
Moreover, in an attempt to elucidate further the variety of physio-
logical roles of AR in mammary gland, we investigated whether
AR may participate in the regulation of the PA/plasmin system,
under both normal and pathological conditions. 
Our results demonstrate that EGF affects the expression of AR
gene as well as protein secretion, in both normal and tumoral
breast epithelial cells. However, whereas a moderate stimulation
of AR expression was induced by 1028 M EGF in normal
mammary cells (210 ± 75% of control), a similar EGF concentra-
tion increased AR expression level to 980% and 550% of control
in the breast cancer epithelial cell lines MDA-MB231 and MCF-7,
respectively. These data are in agreement with reports demon-
strating that the expression of some EGF-related growth factors
including AR is significantly increased in malignant mammary
epithelium relative to normal epithelium (Salomon et al, 1995;
Panico et al, 1996). Gene transcription is dependent on the activa-
tion of specific transcription factors. In tumoral cells, an increase
in amount of oncogenic transcription factors can affect the degree
to which they can regulate gene expression (Fry and Farnham,
1999). Thus, in MCF-7 and MDA-MB231 cells, high level of AR
mRNA induction by EGF might result from high level of activated
transcription factors. Curiously, the inverse pattern was observed
regarding the level of secreted protein, since in response to EGF,
normal cells were able to release in culture medium 5–10 folds
more AR than tumour cells. Martinez-Lacaci et al (1995) have
demonstrated that AR was accumulated into the nucleus of MCF-
7 cells treated with oestradiol, whereas it was predominantly
secreted after treatment with 12-O-tetradecanoyl phorbol-13-
acetate. An immunocytochemical examination of MCF-7 and
MDA-MB231 cells did not enable the detection of any intracel-
lular accumulation of AR following EGF-treatment (not shown),
suggesting that the low level of secreted AR is not due to alter-
ations in secretion process. Alternatively, amphiregulin peptide
quantities produced by tumour cells might be influenced by tran-
scriptional or post-transcriptional events such as impaired stability
of AR mRNA, and/or by the concomitant accumulation in condi-
tioned medium of proteases that degrade AR. Moreover, various
isoforms of AR that differ in the degree of glycosylation and NH2-
terminal processing have been described (Shoyab et al, 1988;
Johnson et al, 1993b; Martinez-Lacaci et al, 1995). Therefore, the
production by tumoral cells of particular AR isoforms unde-
tectable by our enzyme-immunoassay, cannot be excluded and is
presently under investigation. 
A number of published studies indicate that AR may be
involved in a variety of normal physiological events such as dif-
ferentiation of the mammary gland (Kenney et al, 1995).
Nevertheless, AR is more often described for its ability to regulate
the proliferation of cultured cells. Thus, AR can function as a
potent mitogen on a variety of normal epithelial cells including
mammary and prostatic epithelial cells (Li et al, 1992; Kenney
et al, 1993). Our results describing an important growth stimula-
tory activity of AR on normal breast epithelial cells are in agree-
ment with the published data. Also, they are consistent with the
demonstration by Kenney et al (1996) that AR can re-establish
longitudinal ductal proliferation in quiescent mammary glands of
ovariectomized mice suggesting that it may be an important inter-
mediary in glandular development. 
Besides these various physiological functions, AR seems to play
a special role in tumoral cell progression. To this purpose we have
recently demonstrated that antisense expression for AR suppresses
tumorigenicity of transformed breast epithelial cells in vivo (Ma
et al, 1999). Moreover, the presence of AR in breast cancer cells
has been correlated with cancer spread to lymph nodes, suggesting
that it might act to enhance tumour metastasis (Lejeune et al, 1993).
Plasminogen activation is considered a central process in the regu-
lation of pericellular proteolysis that occurs under both normal and
pathological conditions, including cancer invasion. Because high
levels of components of the plasminogen activation system, uPA
but paradoxically also its inhibitor PAi-1 (Foeckens et al, 1992;
Bouchet et al, 1994), have been correlated with a poor prognostic
for breast cancers, the role of AR in the regulation of uPA and PAi-
1 production by normal and tumoral mammary epithelial cells was
further examined. Whereas AR was shown to induce an important
stimulation of normal cell proliferation, the levels of both uPA and
PAi-1 secreted by these cells were affected neither by AR, nor by
EGF. On the contrary, AR induced a dose-dependent accumulation
of uPA and PAi-1 in conditioned culture medium of MCF-7 and
MDA-MB231 cells but failed, as previously reported by Shoyab et
al (1988), to regulate their proliferation. It has to be noted that EGF
was less effective than AR in stimulating protease production by
tumoral cells. The present study further demonstrated that the
increased production of protease induced by AR was accompanied
by an augmentation of the number of tumoral cells able to invade
reconstituted basement membrane in vitro. The presence of a
neutralizing anti-uPA receptor antibody was unable to affect the
invasive properties of both untreated and AR-treated MCF-7 cells
indicating that uPA is not the principal actor of the degradation of
basement membrane by these cells. Given the relative low uPA
protein level detected into conditioned medium of MCF-7 cells, we
propose that uPA quantity required to degrade matrigel was not
attained, even under AR-treatment. Moreover, the ratio PAi-1/uPA
appeared clearly in favour of PAi-1, suggesting that uPA activity
might be efficiently neutralized. Recently, studies have demon-
strated that EGF and AR were able to induce the expression of
matrix metalloproteinases (MPPs) in a variety of tumoral cell lines
(Kondapaka et al, 1997; Sundareshan et al, 1999). Although these
studies have not established a direct link between the increased
production of MMPS and cell invasiveness, we suggest that EGF
and AR might modulate invasion of MCF-7 cells by up-regulating
the expression of member(s) of MPP family. Conversely, the pres-
ence of the antibody reversed the invasive effect of AR on MDA-
MB231 cells, demonstrating that the growth factor increased the
invasiveness of these cells in part by increasing the production of
uPA. Moreover, EGF might enhance this process by increasing the944 M Silvy et al
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production and accumulation of AR protein in the extracellular
compartment. 
In conclusion, the present study provides additional evidence
for the contribution of the AR protein during normal and tumoral
mammary development. Firstly, our data reveal differential beha-
viour of normal versus tumoral breast epithelial cells in regard to
the action of AR. Thus, while AR is a potent stimulator for normal
cell proliferation, it increases the production of uPA and PAi-1
only in tumoral epithelial cells, suggesting that molecular alter-
ations associated to cell transformation may modify the function of
AR. AR, as most of EGF-like growth factors, directly interacts
with EGF-receptor (ErbB1). The fact that AR elicits distinct
biological responses in normal relative to tumoral cells, does not
result from differences in EGF-R content, since similar high
receptor number were measured in HMECs and MDA-MB231
cells (not shown). However, EGF-like growth factors may also
differentially regulate signalling events by activating other ErbB
family receptors through a transmodulation mechanism (Riese et
al, 1996). A corollary is that the activation of these different recep-
tors results in distinct biological responses. Although the presence
of various ErbB family receptors in our HMECs has not been
examined, it can be speculated that the differential activity of AR
in normal versus tumoral cells might result from the activation of
different sets of receptors. In a second step, this study demon-
strates for the first time that AR might promote invasion and
metastasis of a variety of breast tumours by stimulating the
PA/plasmin system. Although the physiological relevance of these
observations needs to be established in vivo, these data suggest
that AR play a special role in the pathogenesis of the breast.
Presently, we can assert that the reduction of the tumorigenecity of
transformed mammary epithelial cells that results of AR-antisens
transfection (Ma et al, 1999) is associated to a reduction of the
expression of uPA in tumours developed into nude mice (manu-
script in preparation). It is probable that a better knowledge of the
function of AR in breast tissue might open new perspectives for
the diagnosis, prognosis and treatment of breast cancer. 
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